Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 168,713 shares of CSTL stock, worth $3.71 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
168,713
Previous 165,458
1.97%
Holding current value
$3.71 Million
Previous $4.72 Million
4.71%
% of portfolio
0.02%
Previous 0.03%
Shares
11 transactions
Others Institutions Holding CSTL
# of Institutions
206Shares Held
25.8MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$66.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$40.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$39.5 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$31.6 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$22 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $578M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...